Form 4: Arrowhead Pharmaceuticals Executive James Hamilton Reports Stock Transactions

James Hamilton, Chief Discovery/Trans Medicine at Arrowhead Pharmaceuticals, reported the acquisition of 100,000 shares and the sale of 32,729 shares of common stock.

Summary

• James Hamilton, Chief Discovery/Trans Medicine at Arrowhead Pharmaceuticals, acquired 100,000 shares of common stock on January 4, 2025, through restricted stock units that will vest over four years.
• On January 6, 2025, Mr. Hamilton sold 21,758 shares at a weighted average price of $19.68 per share, with individual sales ranging from $19.16 to $20.00.
• Also on January 6, 2025, Mr. Hamilton sold an additional 10,971 shares at a weighted average price of $20.11 per share, with individual sales ranging from $20.01 to $20.22.
• These sales were executed under a pre-arranged 10b5-1 trading plan.
• The sales included a partial disposition of restricted stock units to cover tax obligations.
• Following these transactions, Mr. Hamilton beneficially owns 272,122 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative in itself. The transactions are part of a pre-arranged plan and do not indicate any specific sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the pharmaceutical and biotechnology sectors, such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals.
• The vesting schedule of the restricted stock units, with four equal annual installments, is a typical structure for executive compensation packages.
• The reported share sales are within the normal range of insider transactions and do not indicate any unusual activity compared to similar filings from other companies.

Stakeholder Impact

• The stock sales by Mr. Hamilton may have a minor impact on the stock price, but the transactions are part of a pre-arranged plan and are not expected to cause significant fluctuations.
• The vesting of restricted stock units is part of the executive compensation package, which is a standard practice for publicly traded companies.

Key Dates

Keywords

insider trading, stock sale, restricted stock units, Form 4, 10b5-1 trading plan, executive compensation, share transactions, ARWR, Arrowhead Pharmaceuticals